Diasorin Signs A Supplier Agreement With Quest Diagnostics For The Innovative Molecular Multiplexing Platform, Liaison Plex

Original from: Diasorin

Diasorin (FTSE MIB: DIA) today announced the signing of a supplier agreement with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services based in and serving the United States.

Under the terms of the agreement, Diasorin will install 24 LIAISON PLEX systems in 8 Quest Diagnostics laboratories in the U.S. Each LIAISON PLEX® system has 6 chambers allowing for high-volume testing.

Diasorin expects to supply its LIAISON PLEX Respiratory Panel to Quest Diagnostics to serve demand for molecular testing during the upcoming flu season.

This agreement marks a pivotal milestone in Diasorin’s multiplexing strategy and underscores the increasing recognition of the LIAISON PLEX platform’s advanced technical capabilities, usability, and diagnostic accuracy.

“We are proud to see our technology embraced by one of the largest laboratory networks in the U.S.,” said Angelo Rago, President of Luminex. “This agreement validates the value of our multiplexing platform in supporting laboratories to deliver more informed diagnostic insights while maintaining operational simplicity.”

Source: Diasorin Signs A Supplier Agreement With Quest Diagnostics For The Innovative Molecular Multiplexing Platform, Liaison Plex